[Clinical studies of cefpodoxime proxetil in respiratory tract infections].

Abstract

Twelve patients with respiratory tract infections were treated with cefpodoxime proxetil (CS-807, CPDX-PR), a new cephem antibiotic. It was given orally at a dose of 200 mg 2 times a day for 4 approximately 15 days. Its clinical effects were evaluated as excellent in 1 case, good in 9 cases and poor in 2 cases. The efficacy rate was 83.3%. Its bacteriological effects were evaluated as eradication in 5 strains and decrement in 1 strain. The eradication rate was 83.3%. No adverse reactions and disorder of laboratory findings due to CPDX-PR were observed.

• Authors: S Odagiri, K Matsunaga, K Suzuki, K Murohashi, H Takahashi, H Numata, K Takahashi, I Yamaki, S Ishii
• Journal: The Japanese journal of antibiotics (Jpn J Antibiot) Vol. 41 Issue 10 Pg. 1538-44 (Oct 1988) ISSN: 0368-2781 [Print] Japan
• PMID: 3204658 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Cephalosporins
• cefpodoxime proxetil
• Ceftizoxime

Topics

• Administration, Oral
• Adult
• Aged
• Bronchiectasis (drug therapy)
• Bronchitis (drug therapy)
• Ceftizoxime (analogs & derivatives)
• Cephalosporins (administration & dosage, therapeutic use)
• Drug Evaluation
• Female
• Humans
• Male
• Middle Aged
• Respiratory Tract Infections (drug therapy)
• Staphylococcal Infections (drug therapy)